



## Insights Into Hepatocellular Carcinoma – Northeast

Tuesday, April 18, 2023

Speaker/Moderator: Tanios Bekaii-Saab, MD

### AGENDA

Time (ET)	Topic
6.00 PM – 6.15 PM (15 min)	<b>Introduction</b> <ul style="list-style-type: none"> <li>• Program overview</li> <li>• Round-robin introductions</li> <li>• ARS questions</li> </ul>
6.15 PM – 7.20 PM (30-min presentation; 35-min discussion)	<b>First-Line Treatment of Advanced HCC</b> <ul style="list-style-type: none"> <li>• Overview of current data <ul style="list-style-type: none"> <li>– Factors guiding first-line therapy <ul style="list-style-type: none"> <li>▪ Sorafenib vs lenvatinib</li> <li>▪ Incorporation of checkpoint inhibitors <ul style="list-style-type: none"> <li>• Atezolizumab + bevacizumab</li> <li>• Nivolumab</li> <li>• Durvalumab</li> <li>• Pembrolizumab</li> </ul> </li> </ul> </li> </ul> </li> <li>• Reaction and discussion</li> </ul>
7.20 PM – 7.30 PM (10 min)	<b>Break</b>
7.30 PM – 8.45 PM (30-min presentation; 45-min discussion)	<b>Second-Line and Subsequent Therapy for Advanced HCC</b> <ul style="list-style-type: none"> <li>• ARS questions <ul style="list-style-type: none"> <li>– Subsequent-line therapy <ul style="list-style-type: none"> <li>▪ Cabozantinib</li> <li>▪ Nivolumab vs pembrolizumab</li> <li>▪ Ramucirumab (high AFP)</li> <li>▪ Regorafenib</li> <li>▪ Ipilimumab + nivolumab</li> </ul> </li> </ul> </li> <li>• Reaction and discussion</li> </ul>
8.45 PM – 9.00 PM (15 min)	<b>Key Takeaways and Meeting Evaluation</b>